Evidence map›Paper›PMID 31654635›Full record

ArticleGastroenterology2020

Risk Factors and Incidence of Gastric Cancer After Detection of Helicobacter pylori Infection: A Large Cohort Study.

Shria Kumar, David C Metz, Susan Ellenberg, David E Kaplan, David S Goldberg

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 151 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
151citing papers in PubMed, 6 pooled it
30.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

151 citing papers in PubMed, 6 syntheses or guidelines pooled it, 287 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Guideline
  6. Pooled it
  7. FMRP promotes gastric cancer progression via mJournal of translational medicine · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Practice Tips From the UpdatedGastroenterology & hepatology · 2026
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Effect of Helicobacter pylori Treatment on Gastric Cancer Incidence and Mortality.The Korean journal of helicobacter and upper gastrointestinal research · 2025
    Article

91 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Shria KumarDivision of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: shriakumar@gmail.com.
David C MetzDivision of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Susan EllenbergCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
David E KaplanDivision of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Division of Gastroenterology, Veterans Health Administration, Philadelphia, PA.
David S GoldbergCenter for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Division of Digestive Health and Liver Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.
University of Pennsylvania · USUnited States Department of Veterans Affairs · USUniversity of Miami · US

Funding

CLINICAL EPIDEMIOLOGY TRAINING IN GASTROENTEROLOGYT32DK007740 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI James D Lewis · 1997 to 2026
$9.2M
NIDDK NIH HHS T32 DK007740
6 · The paper itself

Abstract

BACKGROUND &

aimsNearly all studies of gastric adenocarcinoma in the United States have relied on national cancer databases, which do not include data on Helicobacter pylori infection, the most well-known risk factor for gastric cancer. We collected data from a large cohort of patients in the United States to calculate the incidence of and risk factors for nonproximal gastric adenocarcinomas after detection of H pylori. Secondary aims included identifying how treatment and eradication affect cancer risk.

methodsWe performed a retrospective cohort study, collecting data from the Veterans Health Administration on 371,813 patients (median age 62 years; 92.3% male) who received a diagnosis of H pylori infection from January 1, 1994, through December 31, 2018. The primary outcome was a diagnosis of distal gastric adenocarcinoma 30 days or more after detection of H pylori infection. We performed a time to event with competing risk analysis (with death before cancer as a competing risk).

resultsThe cumulative incidence of cancer at 5, 10, and 20 years after detection of H pylori infection was 0.37%, 0.5%, and 0.65%, respectively. Factors associated with cancer included older age at time of detection of H pylori infection (subhazard ratio [SHR], 1.13; 95% confidence interval [CI], 1.11-1.15; P < .001), black/African American race (SHR, 2.00; 95% CI, 1.80-2.22), Asian race (SHR, 2.52; 95% CI, 1.64-3.89) (P < .001 for race), Hispanic or Latino ethnicity (SHR, 1.59; 95% CI, 1.34-1.87; P < .001), and history of smoking (SHR, 1.38; 95% CI, 1.25-1.52; P < .001). Women had decreased risk of gastric adenocarcinoma compared with men (SHR, 0.52; 95% CI, 0.40-0.68; P < .001); patients whose H pylori infection was detected based on serum antibody positivity also had a reduced risk of cancer (SHR 0.74; 95% CI, 0.54-1.04; P = .04). Patients who received treatment for their H pylori infection still had an increased risk of gastric cancer (SHR, 1.16; 95% CI, 0.74-1.83; P = .51) but confirmed H pylori eradication after treatment reduced risk of gastric cancer (SHR, 0.24; 95% CI, 0.15-0.41; P < .001).

conclusionsIn a study of 371,813 veterans with a diagnosis of H pylori infection, we found significantly higher risks of gastric cancer in racial and ethnic minorities and smokers. Treatment of H pylori infection decreased risk only if eradication was successful. Studies are needed on the effects of screening high-risk persons and to identify quality measures for diagnosis, resistance patterns, and treatment efficacy.

Indexed as

AdenocarcinomaAgedAge FactorsAntacidsAnti-Bacterial AgentsDrug Therapy, CombinationEthnicityFemaleFollow-Up StudiesHealth Status DisparitiesHelicobacter InfectionsHelicobacter pyloriHumansIncidenceMaleMiddle AgedAntacidsAnti-Bacterial AgentsProton Pump InhibitorsAntibacterial TherapyMicrobeScreeningStomach Cancer

Identifiers

PMID31654635
PMCPMC7010558
OpenAlexW2981358775

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.